Company intelligence / Profile preview

Neudive

Seoul, Seoul Special City, South Koreaneudive.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Neudive’s lead digital therapeutic, Buddy-in (NDTx-01), is a gamified mobile software designed to improve social skills in children and adolescents with autism spectrum disorder and social communication disorder. A randomized controlled pilot clinical trial demonstrated initial safety and efficacy. A confirmatory clinical trial is ongoing as of 2025, aiming for regulatory approval from the Korean Ministry of Food and Drug Safety

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceSoftwareDigital therapeutics (DTx)
Industry: Digital Health Medical Devices

Partnerships

HanAll Biopharma Co., Ltd.Ewha Womans University Center for Child Development and Disability

Beyond the preview

Go deeper on Neudive.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neudive.

Explore the full profile